期刊
JOURNAL OF VIROLOGY
卷 89, 期 16, 页码 8643-8650出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.03635-14
关键词
-
类别
资金
- Bill & Melinda Gates Foundation Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) [38619, 1032144]
- NIH NIAID grants [HHSN27201100016, HHSN266200600005C]
- CHAVI/HVTN Early Stage Investigator Award [5U19AI067854, R01AI106380, R21 AI87382]
- Europrise European grant [LSHP-CT-2006-037611]
- HVTN LC (HIV Vaccine Trials Network grant) [UM1AI068618]
- Duke Division of Laboratory Animal Research
- Duke Center for AIDS Research (CFAR) Immunology Core and Biostatistics and Computational Biology Cores (NIH) [5P30 AI064518]
- NATIONAL CANCER INSTITUTE [ZIABC010350, ZIABC010749] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [UM1AI068614, P30AI064518, UM1AI068618, R01AI106380, ZIAAI005020, U19AI067854, R21AI087382] Funding Source: NIH RePORTER
- OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [P51OD011132] Funding Source: NIH RePORTER
To evaluate antibody specificities induced by simian immunodeficiency virus (SIV) versus human immunodeficiency virus type 1 (HIV-1) envelope antigens in nonhuman primate (NHP), we profiled binding antibody responses to linear epitopes in NHP studies with HIV-1 or SIV immunogens. We found that, overall, HIV-1 Env IgG responses were dominated by V3, with the notable exception of the responses to the vaccine strain A244 Env that were dominated by V2, whereas the anti-SIV mac239 Env responses were dominated by V2 regardless of the vaccine regimen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据